MarketPR
Reports emerged that AstraZeneca and Bristol Myers Squibb held merger discussions, a potential combination that analysts have struggled to justify given AstraZeneca's organic growth profile and the patent liabilities Bristol Myers would carry into any deal.
Neither company has confirmed a definitive agreement.
The numbers AstraZeneca is on track to reach $80 billion in annual sales by 2030, according to analyst Rachel Warren, giving the company one of the strongest organic growth profiles in pharma.
Warren argued that removes the usual rationale for a large acquisition.
Keep reading